ClinicalTrials.gg
CompletedNCT05062590ESOGERUpdated Nov 2, 2026

Evolution and Adaptation to Caregiver of a Socio-geriatric Evaluation

An interventional study of Recommendations in Social Isolation and Aging, sponsored by Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal. Completed at 1 site in Canada. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal · Not applicable, Interventional, and Other

How we know

Updated Nov 2, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
234
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Social Isolation with a site in Canada — 9 open to participants now, 10 under way, none of them phase 3. Social Isolation · Canada.

Enrollment
9th of 29
234 · median 120
Started
2022
with 6 others
No phase
29 of 30
9 open now
Registered
14th of 30
by date
Lead sponsor
4 of 30
Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal

Among the 30 studies in Social Isolation with a site in Canada, this one is the 9th largest by enrollment of the 29 interventional ones that give a count, is one of 7 that started in 2022, is one of 29 with no phase, and was the 14th registered.

Social Isolation

237 studies on the registry are indexed under Social Isolation; 61 are open to participants now.

Browse Social Isolation studies →

Open to participants now

9 of the 30 studies in Social Isolation with a site in Canada are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 34 Social Isolation studies recruiting now, 22 (65%) set no upper age limit and 6 (18%) stop at 75 or younger; 4 take children under 18; 18 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Social Isolation with a site in Canada, or all of them as a file.
02

Study summary

With the COVID-19 pandemic, elderly people (EP) living at home have seen their health deteriorated, thus increasing their needs in support and care. Indeed, while it was estimated that before the pandemic120 000 unattended living at home EP required care and services (taking bath, access to medication and food, etc.), the number doubled after COVID-19. Therefore, the waiting list for socio-medical services for unattended vulnerable clientele without a family doctor grew from 1300 à 1715 EP in a couple of months during the pandemic. With these numbers, it becomes clear that an intervention is needed. Truly, the Institut National d'Excellence en Santé et Services Sociaux (INESSS) conclude that it was pivotal to first identify the most vulnerable EP and second re-orient them according to their needs. Thus the investigator developed the Évaluation et orientation SOcio-GÉRiatrique (ESOGER) questionnaire available on a secure digital plateform enabling both a rapid evaluation and intervention to asses EP needs and provide the adequate ressources. Investigator's previous research has demonstrated that ESOGER is one of the rare clinical tools of first contact in telehealth while being global, multidimensional, and equitable. For this study, the investigator aims to evaluate the effect of ESOGER on EP physical and mental health, loss of autonomy, social isolation, quality of life and ressources consumption.

03

Conditions studied

  • Social Isolation
  • Aging

Browse trials for

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 65 and more
  • Living at home on the territory CIUSSS-Centre-Sud de l'île-de-Montréal (CCSMTL) of Jeanne-Mance
  • Brief Geriatric Assessment (BGA) score of 1/14 or more defining a severly to milidly frail health.

Exclusion criteria

Exclusion Criteria:

  • Principal address outside of the CCSMTL's Jeanne-Mance territory
  • Participate at another clinical trial, to avoid interferences
  • Not understand written or spoken French or English, questionnaires are only available in French and English.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
234 participants (actual)

Study arms

  • Experimental
    Group Intervention

    Experimental: Group 1 The intervention group will take the ESOGER questionnaire at month 0 and month 3 ( beginning and end) and receive recommendations following their needs.

    Other: Recommendations

  • No intervention
    Group control

    The participants will only take the ESOGER questionnaire at month 0 and month 3 without recommendations

Interventions

  • OtherRecommendations

    Ressources recommendations and interventions curated to the needs of the EP such as refering them to a social activity for socially isolated EP

06

What researchers measure

Primary outcomes

  1. COVID-19 symptoms

    presence or not of fever, cough, and shortness of breath (binary question)

    Time frame: 3 months

  2. psychological fraility

    Anxiety verbal analogic scale, score from 0= no anxiety to 10= extremly anxious

    Time frame: 3 months

  3. Social health

    Issues related to medication and food delivery and access to home care. Presence or not of a shortage in food, medication and home care ( binary question)

    Time frame: 3 months

  4. Socio-economic characteristics

    Presence or not of socio-economic problems (binary questions)

    Time frame: 3 months

  5. Participant's Quality of life

    Measured by the EQ-5D scale with two parts, scale 1 score from 1= no problem to 5 ( sever health problems) and scale 2 visual analogic scale score from 0= worst possible health to 100= best possible health.

    Time frame: 3 months

  6. Autonomy

    ADL scale score from 0= very dependent to 6= very independent and IADL scale score 0= not autonomous 4= autonomous.

    Time frame: 3 months

Secondary outcomes

  1. Caregiver burden

    Based on Zarit scale, score from 0= no burden to 16= high caregiver burnder

    Time frame: 3 months

07

Study locations

1 site
  • CRIUGM
    Montreal, Quebec H3W 1W5, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Apr 2026, 48 months.

Of 156 non-industry interventional studies with no phase under Social Isolation, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 36. This study's 48 months is above that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 10 and three quarters within 36.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Jun 2025 → Apr 2026 and completion Mar 2026 → Apr 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2021
First posted
Sep 30, 2021
StartActual
Apr 4, 2022
Primary completionActual
Apr 7, 2026was Jun 2025
CompletionActual
Apr 7, 2026was Mar 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 2, 2026
Sites
1 site added, 1 site removed
Show site
  • CRIUGM · Montreal, Canada
Show 1 removed
  • CRIUGM · Montréal, Canada
Nov 2, 2026
Primary completion
Jun 2025→Apr 7, 2026 (actual)
Nov 2, 2026
Study completion
Mar 2026→Apr 7, 2026 (actual)
Nov 2, 2026
Enrollment
260 (estimated)→234 (actual)
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Recruiting→Completed
    1 site added, 1 site removed
    Show site
    • CRIUGM · Montreal, Canada
    Show 1 removed
    • CRIUGM · Montréal, Canada
    Primary completion Jun 2025→Apr 7, 2026 (now actual)
    Study completion Mar 2026→Apr 7, 2026 (now actual)
    Enrollment 260 (estimated)→234 (actual)
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05062590
Lead sponsor
Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal
Responsible party
Olivier Beauchet (MD, PhD, Senior researcher, Director of laboratory, Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal) — Principal investigator
First posted
Sep 30, 2021
Start date
Apr 4, 2022
Primary completion
Apr 7, 2026
Completion
Apr 7, 2026
Last update
Nov 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion